European Medicines Agency publishes a report suggesting a "possible link" between usage of the Johnson & Johnson COVID-19 vaccine candidate and rare blood clots.
The European Medicines Agency publishes a report suggesting a "possible link" between usage of the Johnson & Johnson COVID-19 vaccine candidate and rare blood clots. The agency maintains, however, that the overall benefits of the vaccine outweigh the risks of side effects.
Herald Premium Archive
This report is for subscribers
Sign in or choose a plan to read this report and the complete Premium retrospective archive.
HealthEuropean Medicines Agency publishes a report suggesting a "possible link" between usage of the Johnson & Johnson COVID-19 vaccine candidate and rare blood clots.
View Premium plansBrowse free archive reportsThe European Medicines Agency publishes a report suggesting a "possible link" between usage of the Johnson & Johnson COVID-19 vaccine candidate and rare blood clots. The agency maintains, however, that the overall benefits of the vaccine outweigh the risks of side effects.